27 June 2018 - In the first half of 2018, Health Canada approved three biosimilars based on three different reference products, bringing the total number of biosimilar approvals to 11, based on 8 reference products.

As previously reported, the Federal Court held a patent for Janssen’s Remicade (infliximab) valid and infringed by Hospira’s biosimilar Inflectra.

Read Lexology article